MRTX 1133
Alternative Names: MRTX-1133Latest Information Update: 09 Jul 2025
At a glance
- Originator Array BioPharma; Mirati Therapeutics
- Developer Mirati Therapeutics; University of Alabama at Birmingham
- Class Antineoplastics; Azabicyclo compounds; Cyclic hydrocarbons; Ethers; Fluorinated hydrocarbons; Naphthols; Pyridines; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer
- No development reported Cancer
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from preclinical trial in Pancreatic cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Preclinical trials in Non-small cell lung cancer in USA (Intraperitoneal), prior to April 2025
- 25 Apr 2025 Pharmacodynamics and adverse events data from a preclinical trial in non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research(AACR-2025)